December 20, 2023
admin
Emcure Pharmaceuticals IPO GMP, Details, Guidance, Subscription Status, allotment @ Chanakyanipothi.com
👉A legacy of 31 Years.
India`s Oldest Investment & IPO website.
👉Most Trusted by Investors across India.
Table of Contents
- GMP
- Reviews
- Subscription
- Allotment
What is the latest news relating to Emcure Pharmaceuticals IPO?
Grey market is expected to have good fancy for the IPO.
What is the latest GMP of Emcure Pharmaceuticals IPO?
Grey market is expected to have good fancy for the IPO.
What are the promoters of Emcure Pharmaceuticals IPO?
SATISH RAMANLAL MEHTA AND SUNIL RAJANIKANT MEHTA are the promoters of the Emcure Pharmaceuticals.
What are the Objects of Emcure Pharmaceuticals IPO?
The Offer comprises the Fresh Issue of Equity Shares and an Offer for Sale.
The Company proposes to utilise the Net Proceeds towards funding of the following objects:
1. Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the
Company; and
2. General corporate purposes.
What is the business of Emcure Pharmaceuticals?
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It is a R&D driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled it to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. It was ranked as (i) the 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT September 2023, (ii) the 4th largest pharmaceutical company by market share in its Covered Markets in terms of Domestic Sales for MAT September 2023, and (iii) the largest pharmaceutical company in the gynecology and human immunodeficiency virus (“HIV”) antivirals therapeutic areas in India in terms of Domestic Sales for MAT September 2023.
Its sales in India contributed to 50.84% and 53.16% of its total revenue from operations for the six months ended September 30, 2023 and the Financial Year 2023, respectively. Between MAT September 2019 and MAT September 2023, its Domestic Sales grew at a CAGR of 10.80%, outperforming the Indian pharmaceutical market (“IPM”), which grew at a CAGR of 8.23%, by 1.3 times. It had a Covered Market presence of 52.14% of the IPM in terms of Domestic Sales for MAT September 2023.
Across all such therapeutic areas, it ranked among the 10 largest pharmaceutical companies in India in terms of Domestic Sales for MAT September 2023. Sales of its iron, chiral, biotherapeutics, injectables and photo-chemistry products contributed to 54.43% and 51.40% of its revenue from sales in India for the six months ended September 30, 2023 and the Financial Year 2023, respectively, demonstrating its approach towards establishing a differentiated product portfolio.
Emcure has demonstrated strong capabilities and a proven track record in building brands. Eight of its brands were ranked among the 300 highest selling brands in the IPM, in terms of Domestic Sales for MAT September 2023. It had 28 brands with Domestic Sales of over Rs 500.00 million for MAT September 2023, as compared to 13 brands for MAT September 2019. In addition, 17 of its top 20 brands were each ranked among the three highest selling brands in their respective therapeutic areas in the IPM, in terms of Domestic Sales for MAT September 2023.
The company also sells its portfolio of differentiated products internationally in over 70 countries.
It is an R&D driven company and its core strength lies in our ability to research, develop and manufacture inhouse specialty pharmaceutical products for high-growth therapeutic areas, for which there is limited competition and high barriers to entry. As of September 30, 2023, it had a team of 552 qualified scientists and five dedicated R&D facilities in India. As of September 30, 2023, it had filed over 1,800 dossiers globally including 204 in the European Union and 133 in Canada. In addition, as of September 30, 2023, it had been granted 201 patents and had 33 pending patent applications in several countries, and had submitted 102 drug master files for APIs with the U.S. Food and Drug Administration (“USFDA”)
Emcure has 13 manufacturing facilities across India.
For more information, click www.emcure.com
Azad Engineering IPO GMP, Particulars & Guidance
| Emcure Pharmaceuticals IPO Details | |
| IPO opens on | ?, 2024 |
| IPO closes on | ?, 2024 |
| Issue Type | Book Built Issue IPO |
| Issue Size | ? Sh /Rs ? Cr |
| * Fresh Issue | ? Sh /Rs 800 Cr |
| * Offer for Sale | 13678839 Sh /Rs ? Cr |
| Face Value per share: | Rs. 10 |
| Price Band | Rs. ? |
| Retail Discount | Rs 0 per share |
| Employee discount | Rs. 0 per share |
| Retail Lot Size | ? Shares |
| Listing will at | BSE, NSE |
| Shares offered in Emcure Pharmaceuticals? | Shares | Rs. in Cr |
| QIB (50 %) | ? | ? |
| NII (15 %) | ? | ? |
| RII (35 %) | ? | ? |
| Tata Motors Shareholders | – | – |
| Total Shares | ? | ? |
| Retail portion will be oversubscribed by | ? Forms. | |
| How to apply in Emcure Pharmaceuticals IPO ? | Amount Rs. | |
| Min Retail Application | – Sh | – |
| Max Retail Application | – Sh | – |
| Small HNI (Min) application | – Sh | – |
| Small HNI (Max) application | – Sh | – |
| Big HNI Application | – Sh | – |
| What is the timetable of Emcure Pharmaceuticals IPO? | |
| IPO opens on | 2024 |
| IPO Closes on | 2024 |
| IPO Allotment on | 2024 |
| Unblocking of ASBA | 2024 |
| Credit of Shares | 2024 |
| Listing on | 2024 |
| Registered Office of Emcure Pharmaceuticals | |
| Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra, India |
|
| Who are the Lead Managers of Emcure Pharmaceuticals IPO? Kotak Mahindra Capital Company Limited Axis Capital Limited Jefferies India Private Limited J. P. Morgan India Private Limited |
|
| Registrar to IPO | |
| Link Intime India Private Limited |
| Emcure Pharmaceuticals IPO Financial & Analytical Ratios | ||||
| Year | Total Income | Net Profit | EPS | RoNW |
| Rs. in Cr | Rs.in Cr | Rs. | % | |
| 2020-21 | 5067 | 607 | 32.11 | 17.25 |
| 2021-22 | 5919 | 703 | 36.62 | 33.32 |
| 2022-23 | 6032 | 562 | 29.42 | 21.27 |
| Book Value of the Share on 31.03.2023 | Rs. | 138.30 | ||
| BV of the Share after the FPO | Rs. | ? | ||
| Offer Price at Cap | Rs. | 524 | ||
| Emcure Pharmaceuticals IPO Ratio Analysis |
|
| Price /EPS | ? |
| Price/Book Value Ratio | ? |
| Price/BV after IPO | ? |
How Emcure Pharmaceuticals IPO compares with the Peers?
Peer Comparison.
| As on date of DRHP | FV | Total | PE |
| Rs. | Income | Ratio of | |
| Rs. In Cr | |||
| Emcure | 10 | 5,986 | ? |
| Dr Reddy’s | 5 | 24670 | 20.45 |
| Cipla | 2 | 22753 | 34.55 |
| Alkem Lab | 2 | 11599 | 58.25 |
| Torren Pharma | 5 | 9,620 | 55.66 |
| Mankind Pharma | 1 | 8749 | 57.8 |
| Abbott Lab | 10 | 5,349 | 51.1 |
| J B Chemicals & | 2 | 3,149 | 55.72 |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Emcure Pharmaceuticals IPO Guidance
This is the much-awaited IPO. Once the price band is finalized, we will provide our guidance.
Quicklinks
